Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1Breast 1

Conditions

Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Adenosarcoma of the uterus 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 16Doxorubicin 13pembrolizumab 11Temozolomide 11X-Rays 10Radiation 10atezolizumab 8Radiotherapy 8Irinotecan 8Phantoms, Imaging 7Nivolumab 7fludarabine 6Vincristine 6Immunoglobulin G 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5cemiplimab 5cabozantinib 5Sirolimus 5Ifosfamide 5Gemcitabine 5Disulfides 5palbociclib 4olaparib 4fludarabine phosphate 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
RAD1901 × Sarcoma × 30 days × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡